Author: Cantini, Fabrizio; Niccoli, Laura; Matarrese, Daniela; Nicastri, Emanuele; Stobbione, Paolo; Goletti, Delia
Title: Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact Cord-id: 1fjb6b8e Document date: 2020_4_23
ID: 1fjb6b8e
Snippet: • Baricitinib at 4 mg/day/orally was given to 12 patients with moderate COVID-19. • In baricitinib-treated patients no adverse events were recorded, after 2 weeks. • Clinical and respiratory parameters significantly improved at 2 weeks. • None of the baricitinib-treated patients required admission to ICU. • Proper control group was missing; this is required to demonstrate the efficacy.
Document: • Baricitinib at 4 mg/day/orally was given to 12 patients with moderate COVID-19. • In baricitinib-treated patients no adverse events were recorded, after 2 weeks. • Clinical and respiratory parameters significantly improved at 2 weeks. • None of the baricitinib-treated patients required admission to ICU. • Proper control group was missing; this is required to demonstrate the efficacy.
Search related documents:
Co phrase search for related documents- long term safety and low number: 1, 2
- lopinavir ritonavir and low number: 1
Co phrase search for related documents, hyperlinks ordered by date